Brokers Set Expectations for Affimed's FY2028 Earnings (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD - Free Report) - HC Wainwright issued their FY2028 earnings per share estimates for Affimed in a note issued to investors on Monday, April 1st. HC Wainwright analyst S. Ramakanth anticipates that the biopharmaceutical company will post earnings per share of ($0.92) for the year. HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for Affimed's current full-year earnings is ($5.92) per share.

A number of other research analysts also recently commented on the company. Wells Fargo & Company dropped their price target on Affimed from $30.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Affimed in a research report on Monday. Finally, StockNews.com initiated coverage on shares of Affimed in a research report on Tuesday, January 2nd. They set a "sell" rating on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, Affimed presently has a consensus rating of "Moderate Buy" and an average target price of $45.00.

Affimed Stock Performance

NASDAQ AFMD traded up $0.22 on Wednesday, hitting $6.66. 252,813 shares of the stock were exchanged, compared to its average volume of 100,360. The business's fifty day moving average is $5.46 and its 200 day moving average is $4.91. The company has a market capitalization of $101.43 million, a PE ratio of -0.83 and a beta of 2.05. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.70 and a quick ratio of 3.67. Affimed has a 52 week low of $2.23 and a 52 week high of $11.10.

Hedge Funds Weigh In On Affimed

Hedge funds have recently added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in shares of Affimed during the 1st quarter valued at $27,000. Schonfeld Strategic Advisors LLC purchased a new position in Affimed in the second quarter worth about $31,000. UBS Group AG grew its stake in shares of Affimed by 42.2% during the 1st quarter. UBS Group AG now owns 47,073 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 13,979 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Affimed by 30.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 3,202 shares during the last quarter. Finally, Advisor Group Holdings Inc. increased its holdings in Affimed by 258.3% during the first quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 6,464 shares during the last quarter. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.